Loading…
Based on limited metadata without access to the full letter text, this warning was issued to Hybrid Pharma, LLC, a pharmaceutical company, on November 30, 2018. The specific violations and detailed subject matter cannot be determined from the available metadata provided. The FDA issued this warning regarding drug products, though the particular issuing office and violation count are not specified in the metadata. A complete review of the full warning letter would be necessary to identify the specific compliance issues and regulatory requirements involved.